SynthesisThe Cochrane database of systematic reviews2009
Topical capsaicin for chronic neuropathic pain in adults.
Synthesis in The Cochrane database of systematic reviews, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 8 syntheses or guidelines pooled it, 175 citations in OpenAlex.
- Herbal medicinal products or preparations for neuropathic pain.The Cochrane database of systematic reviews · 2019Pooled it
- Systematic review of management of chronic pain after surgery.The British journal of surgery · 2017Pooled it
- Topical capsaicin (high concentration) for chronic neuropathic pain in adults.The Cochrane database of systematic reviews · 2017Pooled it
- Interventions for treating pain and disability in adults with complex regional pain syndrome.The Cochrane database of systematic reviews · 2013Pooled it
- Topical NSAIDs for chronic musculoskeletal pain in adults.The Cochrane database of systematic reviews · 2012Pooled it
- Topical capsaicin (low concentration) for chronic neuropathic pain in adults.The Cochrane database of systematic reviews · 2012Pooled it
- Topical NSAIDs for acute pain in adults.The Cochrane database of systematic reviews · 2010Pooled it
- Topical rubefacients for acute and chronic pain in adults.The Cochrane database of systematic reviews · 2009Pooled it
- A Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase I Study of Analgesic/Antihyperalgesic Properties of ASP8477, a Fatty Acid Amide Hydrolase Inhibitor, in Healthy Female Subjects.Pain medicine (Malden, Mass.) · 2018Trial
- Capsaicin induces degeneration of cutaneous autonomic nerve fibers.Annals of neurology · 2010Trial
- Non-Inferiority Study of Two Capsaicin Formulations for Painful Diabetic Neuropathy.Life (Basel, Switzerland) · 2025Article
- Unlocking the potential of capsaicin in oral health (Review).Biomedical reports · 2024Review
- Herpes Zoster and Post-Herpetic Neuralgia-Diagnosis, Treatment, and Vaccination Strategies.Pathogens (Basel, Switzerland) · 2024Review
- An Innovative Topical Medical Device with Hyaluronic Acid and Polypeptides in Patients with Reduced Knee Function.Journal of functional morphology and kinesiology · 2024Article
- Neuropathic Pain in Aged People: An Unresolved Issue Open to Novel Drug Approaches, Focusing on Painful Diabetic Neuropathy.Current neuropharmacology · 2024Review
- Article
- [Perioperative analgesia with nonopioid analgesics : Joint interdisciplinary consensus-based recommendations of the German Pain Society, the German Society of Anaesthesiology and Intensive Care Medicine and the German Society of Surgery].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2021Review
- Evaluation of In Vitro Capsaicin Release and Antimicrobial Properties of Topical Pharmaceutical Formulation.Biomolecules · 2021Article
- Nociceptors protect sickle cell disease mice from vaso-occlusive episodes and chronic organ damage.The Journal of experimental medicine · 2021Article
- Regulation of Pain Genes-Capsaicin vs Resiniferatoxin: Reassessment of Transcriptomic Data.Frontiers in pharmacology · 2020Article
Corrections and comments
- Commented on by
- Updated by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTopical creams with capsaicin are used to treat pain from a wide range of chronic conditions including neuropathic pain. Following application to the skin capsaicin causes enhanced sensitivity to noxious stimuli, followed by a period with reduced sensitivity and, after repeated applications, persistent desensitisation. There is uncertainty about the efficacy and tolerability of capsaicin for treating painful chronic neuropathies.
objectivesTo review the evidence from controlled trials on the efficacy and tolerability of topically applied capsaicin in chronic neuropathic pain in adults. SEARCH STRATEGY: Cochrane CENTRAL, MEDLINE, EMBASE and Oxford Pain Relief Database, searched in May 2009. SELECTION CRITERIA: Randomised, double blind, placebo controlled studies of at least six weeks' duration, using topical capsaicin to treat neuropathic pain. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed trial quality and validity, and extracted data. Information was extracted on numbers of participants with pain relief (clinical improvement) after at least six weeks, and with local skin reactions, and used to calculate relative risk and numbers needed to treat to benefit (NNT) and harm (NNH). Details of definition of pain relief and specific adverse events were sought. MAIN
resultsSix studies (389 participants in total) compared regular application of low dose (0.075%) capsaicin cream with placebo cream; the NNT for any pain relief over six to eight weeks was 6.6 (4.1 to 17). Two studies (709 participants in total) compared a single application of high dose (8%) capsaicin patch with placebo patch; the NNT for >/= 30% pain relief over twelve weeks was 12 (6.4 to 70). Local skin reactions were more common with capsaicin, usually tolerable, and attenuated with time; the NNH for repeated low dose application was 2.5 (2.1 to 3.1). There were insufficient data to analyse either data set by condition or outcome definition. All studies satisfied minimum criteria for quality and validity, but maintenance of blinding remains a potential problem. AUTHORS'
conclusionsCapsaicin, either as repeated application of a low dose (0.075%) cream, or a single application of a high dose (8%) patch may provide a degree of pain relief to some patients with painful neuropathic conditions. Local skin irritation, which is often mild and transient but may lead to withdrawal, is common. Systemic adverse effects are rare. Estimates of benefit and harm are not robust due to limited amounts of data for different neuropathic conditions and inconsistent outcome definition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.